ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
General Health & Fitness
Health & Wellness
Coronavirus COVID-19 Update: Hydroxychloroquine and Other Treatments
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 175447" data-attributes="member: 3"><p>Randomized Controlled Trials in Progress (Thanks to Medscape)</p><p></p><p><span style="font-size: 18px"><strong><strong>COVID-19 RCTs</strong></strong></span></p><table class='post-table ' style='width: 100%'><tr><th ><p>Therapy</p></th><th ><p>Trial Name</p></th><th ><p>Proposed # of Patients</p></th><th ><p>Participating Countries</p></th><th ><p>Primary Completion Date</p></th></tr><tr><th ><p>Remdesivir RCTs</p></th><td></td><td></td><td></td><td></td></tr><tr><td ><p>Remdesivir</p></td><td ><p><a href="https://clinicaltrials.gov/show/NCT04252664" target="_blank">Mild/Moderate 2019-nCoV Remdesivir RCT</a></p></td><td ><p>308</p></td><td ><p>China</p></td><td ><p>April 10, 2020</p></td></tr><tr><td ><p>Remdesivir</p></td><td ><p><a href="https://clinicaltrials.gov/show/NCT04257656" target="_blank">Severe 2019-nCoV Remdesivir RCT</a></p></td><td ><p>453</p></td><td ><p>China</p></td><td ><p>April 3, 2020</p></td></tr><tr><td ><p>Remdesivir</p></td><td ><p><a href="https://clinicaltrials.gov/show/NCT04292730" target="_blank">Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</a></p></td><td ><p>600</p></td><td ><p>US, Hong Kong, South Korea, Singapore, Taiwan</p></td><td ><p>May 1, 2020</p></td></tr><tr><td ><p>Remdesivir</p></td><td ><p><a href="https://clinicaltrials.gov/show/NCT04292899" target="_blank">Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19)</a></p></td><td ><p>400</p></td><td ><p>US, Hong Kong, South Korea, Singapore, Taiwan</p></td><td ><p>May 1, 2020</p></td></tr><tr><td ><p>Remdesivir</p></td><td ><p><a href="https://clinicaltrials.gov/show/NCT04280705" target="_blank">Adaptive COVID-19 Treatment Trial (ACTT) (NIH supported)</a></p></td><td ><p>440</p></td><td ><p>US, Japan, South Korea, Singapore</p></td><td ><p>April 1, 2023</p></td></tr><tr><td ><p>Remdesivir, lopinavir-ritonavir, interferon, hydroxychloroquine</p></td><td ><p><a href="https://clinicaltrials.gov/show/NCT04315948" target="_blank">DisCoVeRy: Trial of Treatments for COVID-19 in Hospitalized Adults</a></p></td><td ><p>3100</p></td><td ><p>France</p></td><td ><p>March 1, 2023</p></td></tr><tr><th ><p>Lopinavir/Ritonavir RCTs</p></th><td></td><td></td><td></td><td></td></tr><tr><td ><p>Lopinavir-ritonavir, anakinra, macrolides, corticosteroids, interferon</p></td><td ><p><a href="https://www.cmaj.ca/content/cmaj/early/2020/03/26/cmaj.200438.full.pdf" target="_blank">REMAP-CAP: A randomised, embedded, multi-factorial, adaptive platform trial for community-acquired pneumonia</a></p></td><td ><p>No maximum</p></td><td ><p>Canada and 13 other countries (Australia, NZ, UK, "a dozen EU countries"), 50 sites</p></td><td ><p>End April/Early May 2020</p></td></tr><tr><td ><p>Lopinavir-ritonavir, hydroxychloroquine</p></td><td ><p><a href="https://clinicaltrials.gov/show/NCT04307693" target="_blank">Comparison of lopinavir-ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)</a></p></td><td ><p>150</p></td><td ><p>South Korea</p></td><td ><p>May 1, 2020</p></td></tr><tr><td ><p>Lopinavir-ritonavir, hydroxychloroquine, remdesivir</p></td><td ><p><a href="https://clinicaltrials.gov/show/NCT04330690" target="_blank">CATCO: Canadian Treatments for COVID-19 trial - Canadian Arm of the WHO SOLIDARITY trial</a></p></td><td ><p>440</p></td><td ><p>Canada plus 45 countries so far</p></td><td ><p>March 18, 2022</p></td></tr><tr><td ><p>Lopinavir-ritonavir, interferon, Chinese medicine</p></td><td ><p><a href="https://clinicaltrials.gov/show/NCT04251871" target="_blank">Treatment and Prevention of Traditional Chinese Medicines (TCMs) on 2019-nCoV Infection</a></p></td><td ><p>150</p></td><td ><p>China</p></td><td ><p>January 22, 2021</p></td></tr><tr><td ><p>Lopinavir-ritonavir, oseltamivir, arbidol hydrochloride</p></td><td ><p><a href="https://clinicaltrials.gov/show/NCT04255017" target="_blank">A Prospective/Retrospective, Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia</a></p></td><td ><p>400</p></td><td ><p>China</p></td><td ><p>June 1, 2020</p></td></tr><tr><td ><p>Lopinavir-ritonavir, ribavirin, interferon</p></td><td ><p><a href="https://clinicaltrials.gov/show/NCT04276688" target="_blank">Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment</a></p></td><td ><p>70</p></td><td ><p>Hong Kong</p></td><td ><p>January 31, 2022</p></td></tr><tr><td ><p>Remdesivir, lopinavir-ritonavir, interferon, hydroxychloroquine</p></td><td ><p><a href="https://clinicaltrials.gov/show/NCT04315948" target="_blank">DisCoVeRy: Trial of Treatments for COVID-19 in Hospitalized Adults</a></p></td><td ><p>3100</p></td><td ><p>France, Belgium, German, the Netherlands, Spain, Sweden, UK</p></td><td ><p>March 1, 2023</p></td></tr><tr><td ><p>Lopinavir-ritonavir</p></td><td ><p><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2001282?articleTools=true" target="_blank">A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe COVID-19</a></p></td><td ><p>199</p></td><td ><p>China</p></td><td ><p>February 3, 2020</p></td></tr><tr><td ><p>Lopinavir-ritonavir</p></td><td ><p><a href="https://clinicaltrials.gov/show/NCT04321174" target="_blank">CORIPREV-LR: COVID-19 Ring-based Prevention Trial With Lopinavir-Ritonavir</a></p></td><td ><p>1220</p></td><td ><p>Canada</p></td><td ><p>March 31, 2021</p></td></tr><tr><th ><p>Other Antiviral RCTs</p></th><td></td><td></td><td></td><td></td></tr><tr><td ><p>Arbidol (antiviral), bromhexine hydrochloride (mucolytic), interferon</p></td><td ><p><a href="https://clinicaltrials.gov/show/NCT04273763" target="_blank">Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)</a></p></td><td ><p>60</p></td><td ><p>China</p></td><td ><p>April 15, 2020</p></td></tr><tr><td ><p>Darunavir, cobicistat</p></td><td ><p><a href="https://clinicaltrials.gov/show/NCT04252274" target="_blank">DACO-nCoV: Efficacy and Safety of Darunavir and Cobicistat for Treatment of Pneumonia Caused by 2019-nCoV</a></p></td><td ><p>30</p></td><td ><p>China</p></td><td ><p>August 31, 2020</p></td></tr><tr><td ><p>Favipiravir, oseltamivir, protease-inhibitor combinations</p></td><td ><p><a href="https://clinicaltrials.gov/show/NCT04303299" target="_blank">THDMS-COVID19: Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Hydroxychloroquine for Treatment of COVID19: A Randomized Control Trial (THDMS-COVID19)</a></p></td><td ><p>80</p></td><td ><p>Thailand</p></td><td ><p>October 31, 2020</p></td></tr><tr><th ><p>Investigational Immunotherapy RCTs</p></th><td></td><td></td><td></td><td></td></tr><tr><td ><p>Lopinavir-ritonavir, anakinra, macrolides, corticosteroids, interferon</p></td><td ><p><a href="https://clinicaltrials.gov/show/NCT02735707" target="_blank">REMAP-CAP: A randomised, embedded, multi-factorial, adaptive platform trial for community-acquired pneumonia</a></p></td><td ><p>No maximum</p></td><td ><p>Canada and 13 other countries (Australia, NZ, UK, "a dozen EU countries"), 50 sites</p></td><td ><p>End April/Early May 2020</p></td></tr><tr><td ><p>Bevacizumab</p></td><td ><p><a href="https://clinicaltrials.gov/show/NCT04305106" target="_blank">BEST-RCT: Bevacizumab in Severe or Critically Severe Patients With COVID-19 Pneumonia-RCT</a></p></td><td ><p>118</p></td><td ><p>China</p></td><td ><p>June 30, 2020</p></td></tr><tr><td ><p>Emapalumab, anakinra</p></td><td ><p><a href="https://clinicaltrials.gov/show/NCT04324021" target="_blank">Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.</a></p></td><td ><p>54</p></td><td ><p>Italy</p></td><td ><p>July 1, 2020</p></td></tr><tr><td ><p>CD24Fc</p></td><td ><p><a href="https://clinicaltrials.gov/show/NCT04317040" target="_blank">SAC-COVID: CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment</a></p></td><td ><p>230</p></td><td ><p>US</p></td><td ><p>May 1, 2021</p></td></tr><tr><td ><p>Tocilizumab, favipiravir</p></td><td ><p><a href="https://clinicaltrials.gov/show/NCT04310228" target="_blank">Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019</a></p></td><td ><p>150</p></td><td ><p>China</p></td><td ><p>May 1, 2020</p></td></tr><tr><td ><p>"PD-1 blocking antibody", thymosin</p></td><td ><p><a href="https://clinicaltrials.gov/show/NCT04268537" target="_blank">Immunoregulatory Therapy for 2019-nCoV</a></p></td><td ><p>120</p></td><td ><p>China</p></td><td ><p>April 30, 2020</p></td></tr><tr><td ><p>Sarilumab</p></td><td ><p><a href="https://clinicaltrials.gov/show/NCT04324073" target="_blank">CORIMUNO-19 - SARI: Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial -</a></p></td><td ><p>180</p></td><td ><p>France</p></td><td ><p>March 26, 2021</p></td></tr><tr><td ><p>Sarilumab</p></td><td ><p><a href="https://clinicaltrials.gov/show/NCT04315298" target="_blank">Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19</a></p></td><td ><p>400</p></td><td ><p>US</p></td><td ><p>March 16, 2021</p></td></tr><tr><td ><p>ASC09F, ritonavir, oseltamivir</p></td><td ><p><a href="https://clinicaltrials.gov/show/NCT04261270" target="_blank">A Randomized, Open, Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia</a></p></td><td ><p>60</p></td><td ><p>China</p></td><td ><p>May 1, 2020</p></td></tr><tr><td ><p>Tocilizumab</p></td><td ><p><a href="https://clinicaltrials.gov/show/NCT04320615" target="_blank">COVACTA: A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</a></p></td><td ><p>330</p></td><td ><p>US</p></td><td ><p>August 31, 2021</p></td></tr><tr><td ><p>Tocilizumab, sarilumab</p></td><td ><p><a href="https://clinicaltrials.gov/show/NCT04322773" target="_blank">TOCIVID: Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure</a></p></td><td ><p>200</p></td><td ><p>Denmark</p></td><td ><p>June 1, 2021</p></td></tr><tr><th ><p>Human Product RCTs</p></th><td></td><td></td><td></td><td></td></tr><tr><td ><p>Convalescent plasma</p></td><td ><p><a href="https://clinicaltrials.gov/show/NCT04323800" target="_blank">CSSC-OO1: Efficacy and Safety Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune Plasma) Among Adults Exposed to COVID-19</a></p></td><td ><p>150</p></td><td ><p>US</p></td><td ><p>December 31, 2022</p></td></tr><tr><td ><p>Stem cells</p></td><td ><p><a href="https://clinicaltrials.gov/show/NCT04273646" target="_blank">Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia</a></p></td><td ><p>48</p></td><td ><p>China</p></td><td ><p>June 30, 2020</p></td></tr><tr><td ><p>Stem cells</p></td><td ><p><a href="https://clinicaltrials.gov/show/NCT04288102" target="_blank">Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19)</a></p></td><td ><p>90</p></td><td ><p>China</p></td><td ><p>December 31, 2020</p></td></tr><tr><td ><p>Natural-killer cells</p></td><td ><p><a href="https://clinicaltrials.gov/show/NCT04280224" target="_blank">NK Cells Treatment for Novel Coronavirus Pneumonia</a></p></td><td ><p>30</p></td><td ><p>China</p></td><td ><p>September 30, 2020</p></td></tr><tr><th ><p>Vitamin C RCTs</p></th><td></td><td></td><td></td><td></td></tr><tr><td ><p>Vitamin C (high-dose IV)</p></td><td ><p><a href="https://clinicaltrials.gov/show/NCT03680274" target="_blank">LOVIT: Lessening Organ Dysfunction With VITamin C</a></p></td><td ><p>800</p></td><td ><p>Canada</p></td><td ><p>December 31, 2021</p></td></tr><tr><td ><p>Vitamin C (high-dose IV)</p></td><td ><p><a href="https://clinicaltrials.gov/show/NCT04264533" target="_blank">Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia</a></p></td><td ><p>140</p></td><td ><p>China</p></td><td ><p>September 30, 2020</p></td></tr><tr><th ><p>(Hydroxy)Chloroquine RCTs</p></th><td></td><td></td><td></td><td></td></tr><tr><td ><p>Chloroquine, azithromycin</p></td><td ><p><a href="https://clinicaltrials.gov/show/NCT04324463" target="_blank">ACT COVID19: Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial</a></p></td><td ><p>1500</p></td><td ><p>Canada "+ international"</p></td><td ><p>September 30, 2020</p></td></tr><tr><td ><p>Hydroxychloroquine</p></td><td ><p><a href="https://clinicaltrials.gov/ct2/show/NCT04308668?term=NCT04308668&draw=2&rank=1" target="_blank">COVID-19 PEP: Post-Exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2</a></p></td><td ><p>3000</p></td><td ><p>Canada, US</p></td><td ><p>April 21, 2020</p></td></tr><tr><td ><p>Hydroxychloroquine</p></td><td ><p><a href="https://clinicaltrials.gov/show/NCT04261517" target="_blank">Efficacy and Safety of Hydroxychloroquine for Treatment of Pneumonia Caused by 2019-nCoV (HC-nCoV )</a></p></td><td ><p>30</p></td><td ><p>China</p></td><td ><p>February 25, 2020</p></td></tr><tr><td ><p>Hydroxychloroquine</p></td><td ><p><a href="https://www.medrxiv.org/content/10.1101/2020.03.22.20040758v2" target="_blank">Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial</a></p></td><td ><p>62</p></td><td ><p>China</p></td><td ><p>February 28, 2020</p></td></tr><tr><td ><p>Hydroxychloroquine</p></td><td ><p><a href="https://clinicaltrials.gov/show/NCT04318444" target="_blank">Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19) [includes treatment of early symptoms]</a></p></td><td ><p>1600</p></td><td ><p>US</p></td><td ><p>March 1, 2021</p></td></tr><tr><td ><p>Hydroxychloroquine, azithromycin</p></td><td ><p><a href="https://clinicaltrials.gov/show/NCT04321278" target="_blank">Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</a></p></td><td ><p>440</p></td><td ><p>Brazil</p></td><td ><p>August 30, 2020</p></td></tr><tr><th ><p>Other RCTs</p></th><td></td><td></td><td></td><td></td></tr><tr><td ><p>Chinese medicine</p></td><td ><p><a href="https://clinicaltrials.gov/show/NCT04278963" target="_blank">Yinhu Qingwen Decoction for the Treatment of Mild/Common CoVID-19</a></p></td><td ><p>300</p></td><td ><p>China</p></td><td ><p>January 1, 2021</p></td></tr><tr><td ><p>Chinese medicine</p></td><td ><p><a href="https://clinicaltrials.gov/show/NCT04310865" target="_blank">Yinhu Qingwen Granula for the Treatment of Severe CoVID-19</a></p></td><td ><p>116</p></td><td ><p>China</p></td><td ><p>March 30, 2021</p></td></tr><tr><td ><p>Chinese medicine, N-acetylcysteine (cysteine supplement)</p></td><td ><p><a href="https://clinicaltrials.gov/show/NCT04279197" target="_blank">Treatment of Pulmonary Fibrosis Due to 2019-nCoV Pneumonia With Fuzheng Huayu</a></p></td><td ><p>136</p></td><td ><p>China</p></td><td ><p>December 1, 2022</p></td></tr><tr><td ><p>Colchicine</p></td><td ><p><a href="https://clinicaltrials.gov/show/NCT04322682" target="_blank">COLCORONA: Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)</a></p></td><td ><p>6000</p></td><td ><p>Canada</p></td><td ><p>September 1, 2020</p></td></tr><tr><td ><p>Immunoglobulin</p></td><td ><p><a href="https://clinicaltrials.gov/show/NCT04261426" target="_blank">The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia</a></p></td><td ><p>80</p></td><td ><p>China</p></td><td ><p>April 30, 2020</p></td></tr><tr><td ><p>Interferon, arbidol hydrochloride</p></td><td ><p><a href="https://clinicaltrials.gov/show/NCT04254874" target="_blank">A Prospective/Retrospective, Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia</a></p></td><td ><p>100</p></td><td ><p>China</p></td><td ><p>June 1, 2020</p></td></tr><tr><td ><p>Losartan</p></td><td ><p><a href="https://clinicaltrials.gov/show/NCT04311177" target="_blank">Losartan for Patients With COVID-19 Not Requiring Hospitalization</a></p></td><td ><p>516</p></td><td ><p>US</p></td><td ><p>April 1, 2021</p></td></tr><tr><td ><p>Losartan</p></td><td ><p><a href="https://clinicaltrials.gov/show/NCT04312009" target="_blank">Losartan for Patients With COVID-19 Requiring Hospitalization</a></p></td><td ><p>200</p></td><td ><p>US</p></td><td ><p>April 1, 2021</p></td></tr><tr><td ><p>Methylprednisolone</p></td><td ><p><a href="https://clinicaltrials.gov/show/NCT04244591" target="_blank">Steroids-SARI: Glucocorticoid Therapy for Novel Coronavirus Critically Ill Patients With Severe Acute Respiratory Failure</a></p></td><td ><p>80</p></td><td ><p>China</p></td><td ><p>April 25, 2020</p></td></tr><tr><td ><p>Methylprednisolone</p></td><td ><p><a href="https://clinicaltrials.gov/show/NCT04263402" target="_blank">The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia</a></p></td><td ><p>100</p></td><td ><p>China</p></td><td ><p>June 1, 2020</p></td></tr><tr><td ><p>Methylprednisolone</p></td><td ><p><a href="https://clinicaltrials.gov/show/NCT04273321" target="_blank">Efficacy and Safety of Corticosteroids in COVID-19</a></p></td><td ><p>400</p></td><td ><p>China</p></td><td ><p>May 1, 2020</p></td></tr><tr><td ><p>Nitric oxide gas</p></td><td ><p><a href="https://clinicaltrials.gov/show/NCT04305457" target="_blank">NoCovid: Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19</a></p></td><td ><p>240</p></td><td ><p>US, China, Italy</p></td><td ><p>April 1, 2021</p></td></tr><tr><td ><p>Nitric oxide gas</p></td><td ><p><a href="https://clinicaltrials.gov/show/NCT04306393" target="_blank">NOSARSCOVID: Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19</a></p></td><td ><p>200</p></td><td ><p>US, China, Italy</p></td><td ><p>March 21, 2021</p></td></tr><tr><td ><p>PUL-042 inhalation solution</p></td><td ><p><a href="https://clinicaltrials.gov/show/NCT04312997" target="_blank">PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection</a></p></td><td ><p>100</p></td><td ><p>US</p></td><td ><p>September 1, 2020</p></td></tr><tr><td ><p>Tetrandrine</p></td><td ><p><a href="https://clinicaltrials.gov/show/NCT04308317" target="_blank">TT-NPC: Tetrandrine Tablets Used in the Treatment of COVID-19</a></p></td><td ><p>60</p></td><td ><p>China</p></td><td ><p>March 1, 2021</p></td></tr></table></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 175447, member: 3"] Randomized Controlled Trials in Progress (Thanks to Medscape) [SIZE=18px][B][B]COVID-19 RCTs[/B][/B][/SIZE] [TABLE][TR][TH]Therapy[/TH][TH]Trial Name[/TH][TH]Proposed # of Patients[/TH][TH]Participating Countries[/TH][TH]Primary Completion Date[/TH][/TR] [TR][TH]Remdesivir RCTs[/TH][TD] [/TD][TD] [/TD][TD] [/TD][TD] [/TD][/TR] [TR][TD] Remdesivir [/TD][TD] [URL='https://clinicaltrials.gov/show/NCT04252664']Mild/Moderate 2019-nCoV Remdesivir RCT[/URL] [/TD][TD] 308 [/TD][TD] China [/TD][TD] April 10, 2020 [/TD][/TR] [TR][TD] Remdesivir [/TD][TD] [URL='https://clinicaltrials.gov/show/NCT04257656']Severe 2019-nCoV Remdesivir RCT[/URL] [/TD][TD] 453 [/TD][TD] China [/TD][TD] April 3, 2020 [/TD][/TR] [TR][TD] Remdesivir [/TD][TD] [URL='https://clinicaltrials.gov/show/NCT04292730']Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment[/URL] [/TD][TD] 600 [/TD][TD] US, Hong Kong, South Korea, Singapore, Taiwan [/TD][TD] May 1, 2020 [/TD][/TR] [TR][TD] Remdesivir [/TD][TD] [URL='https://clinicaltrials.gov/show/NCT04292899']Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19)[/URL] [/TD][TD] 400 [/TD][TD] US, Hong Kong, South Korea, Singapore, Taiwan [/TD][TD] May 1, 2020 [/TD][/TR] [TR][TD] Remdesivir [/TD][TD] [URL='https://clinicaltrials.gov/show/NCT04280705']Adaptive COVID-19 Treatment Trial (ACTT) (NIH supported)[/URL] [/TD][TD] 440 [/TD][TD] US, Japan, South Korea, Singapore [/TD][TD] April 1, 2023 [/TD][/TR] [TR][TD] Remdesivir, lopinavir-ritonavir, interferon, hydroxychloroquine [/TD][TD] [URL='https://clinicaltrials.gov/show/NCT04315948']DisCoVeRy: Trial of Treatments for COVID-19 in Hospitalized Adults[/URL] [/TD][TD] 3100 [/TD][TD] France [/TD][TD] March 1, 2023 [/TD][/TR] [TR][TH]Lopinavir/Ritonavir RCTs[/TH][TD] [/TD][TD] [/TD][TD] [/TD][TD] [/TD][/TR] [TR][TD] Lopinavir-ritonavir, anakinra, macrolides, corticosteroids, interferon [/TD][TD] [URL='https://www.cmaj.ca/content/cmaj/early/2020/03/26/cmaj.200438.full.pdf']REMAP-CAP: A randomised, embedded, multi-factorial, adaptive platform trial for community-acquired pneumonia[/URL] [/TD][TD] No maximum [/TD][TD] Canada and 13 other countries (Australia, NZ, UK, "a dozen EU countries"), 50 sites [/TD][TD] End April/Early May 2020 [/TD][/TR] [TR][TD] Lopinavir-ritonavir, hydroxychloroquine [/TD][TD] [URL='https://clinicaltrials.gov/show/NCT04307693']Comparison of lopinavir-ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)[/URL] [/TD][TD] 150 [/TD][TD] South Korea [/TD][TD] May 1, 2020 [/TD][/TR] [TR][TD] Lopinavir-ritonavir, hydroxychloroquine, remdesivir [/TD][TD] [URL='https://clinicaltrials.gov/show/NCT04330690']CATCO: Canadian Treatments for COVID-19 trial - Canadian Arm of the WHO SOLIDARITY trial[/URL] [/TD][TD] 440 [/TD][TD] Canada plus 45 countries so far [/TD][TD] March 18, 2022 [/TD][/TR] [TR][TD] Lopinavir-ritonavir, interferon, Chinese medicine [/TD][TD] [URL='https://clinicaltrials.gov/show/NCT04251871']Treatment and Prevention of Traditional Chinese Medicines (TCMs) on 2019-nCoV Infection[/URL] [/TD][TD] 150 [/TD][TD] China [/TD][TD] January 22, 2021 [/TD][/TR] [TR][TD] Lopinavir-ritonavir, oseltamivir, arbidol hydrochloride [/TD][TD] [URL='https://clinicaltrials.gov/show/NCT04255017']A Prospective/Retrospective, Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia[/URL] [/TD][TD] 400 [/TD][TD] China [/TD][TD] June 1, 2020 [/TD][/TR] [TR][TD] Lopinavir-ritonavir, ribavirin, interferon [/TD][TD] [URL='https://clinicaltrials.gov/show/NCT04276688']Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment[/URL] [/TD][TD] 70 [/TD][TD] Hong Kong [/TD][TD] January 31, 2022 [/TD][/TR] [TR][TD] Remdesivir, lopinavir-ritonavir, interferon, hydroxychloroquine [/TD][TD] [URL='https://clinicaltrials.gov/show/NCT04315948']DisCoVeRy: Trial of Treatments for COVID-19 in Hospitalized Adults[/URL] [/TD][TD] 3100 [/TD][TD] France, Belgium, German, the Netherlands, Spain, Sweden, UK [/TD][TD] March 1, 2023 [/TD][/TR] [TR][TD] Lopinavir-ritonavir [/TD][TD] [URL='https://www.nejm.org/doi/pdf/10.1056/NEJMoa2001282?articleTools=true']A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe COVID-19[/URL] [/TD][TD] 199 [/TD][TD] China [/TD][TD] February 3, 2020 [/TD][/TR] [TR][TD] Lopinavir-ritonavir [/TD][TD] [URL='https://clinicaltrials.gov/show/NCT04321174']CORIPREV-LR: COVID-19 Ring-based Prevention Trial With Lopinavir-Ritonavir[/URL] [/TD][TD] 1220 [/TD][TD] Canada [/TD][TD] March 31, 2021 [/TD][/TR] [TR][TH]Other Antiviral RCTs[/TH][TD] [/TD][TD] [/TD][TD] [/TD][TD] [/TD][/TR] [TR][TD] Arbidol (antiviral), bromhexine hydrochloride (mucolytic), interferon [/TD][TD] [URL='https://clinicaltrials.gov/show/NCT04273763']Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)[/URL] [/TD][TD] 60 [/TD][TD] China [/TD][TD] April 15, 2020 [/TD][/TR] [TR][TD] Darunavir, cobicistat [/TD][TD] [URL='https://clinicaltrials.gov/show/NCT04252274']DACO-nCoV: Efficacy and Safety of Darunavir and Cobicistat for Treatment of Pneumonia Caused by 2019-nCoV[/URL] [/TD][TD] 30 [/TD][TD] China [/TD][TD] August 31, 2020 [/TD][/TR] [TR][TD] Favipiravir, oseltamivir, protease-inhibitor combinations [/TD][TD] [URL='https://clinicaltrials.gov/show/NCT04303299']THDMS-COVID19: Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Hydroxychloroquine for Treatment of COVID19: A Randomized Control Trial (THDMS-COVID19)[/URL] [/TD][TD] 80 [/TD][TD] Thailand [/TD][TD] October 31, 2020 [/TD][/TR] [TR][TH]Investigational Immunotherapy RCTs[/TH][TD] [/TD][TD] [/TD][TD] [/TD][TD] [/TD][/TR] [TR][TD] Lopinavir-ritonavir, anakinra, macrolides, corticosteroids, interferon [/TD][TD] [URL='https://clinicaltrials.gov/show/NCT02735707']REMAP-CAP: A randomised, embedded, multi-factorial, adaptive platform trial for community-acquired pneumonia[/URL] [/TD][TD] No maximum [/TD][TD] Canada and 13 other countries (Australia, NZ, UK, "a dozen EU countries"), 50 sites [/TD][TD] End April/Early May 2020 [/TD][/TR] [TR][TD] Bevacizumab [/TD][TD] [URL='https://clinicaltrials.gov/show/NCT04305106']BEST-RCT: Bevacizumab in Severe or Critically Severe Patients With COVID-19 Pneumonia-RCT[/URL] [/TD][TD] 118 [/TD][TD] China [/TD][TD] June 30, 2020 [/TD][/TR] [TR][TD] Emapalumab, anakinra [/TD][TD] [URL='https://clinicaltrials.gov/show/NCT04324021']Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.[/URL] [/TD][TD] 54 [/TD][TD] Italy [/TD][TD] July 1, 2020 [/TD][/TR] [TR][TD] CD24Fc [/TD][TD] [URL='https://clinicaltrials.gov/show/NCT04317040']SAC-COVID: CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment[/URL] [/TD][TD] 230 [/TD][TD] US [/TD][TD] May 1, 2021 [/TD][/TR] [TR][TD] Tocilizumab, favipiravir [/TD][TD] [URL='https://clinicaltrials.gov/show/NCT04310228']Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019[/URL] [/TD][TD] 150 [/TD][TD] China [/TD][TD] May 1, 2020 [/TD][/TR] [TR][TD] "PD-1 blocking antibody", thymosin [/TD][TD] [URL='https://clinicaltrials.gov/show/NCT04268537']Immunoregulatory Therapy for 2019-nCoV[/URL] [/TD][TD] 120 [/TD][TD] China [/TD][TD] April 30, 2020 [/TD][/TR] [TR][TD] Sarilumab [/TD][TD] [URL='https://clinicaltrials.gov/show/NCT04324073']CORIMUNO-19 - SARI: Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial -[/URL] [/TD][TD] 180 [/TD][TD] France [/TD][TD] March 26, 2021 [/TD][/TR] [TR][TD] Sarilumab [/TD][TD] [URL='https://clinicaltrials.gov/show/NCT04315298']Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19[/URL] [/TD][TD] 400 [/TD][TD] US [/TD][TD] March 16, 2021 [/TD][/TR] [TR][TD] ASC09F, ritonavir, oseltamivir [/TD][TD] [URL='https://clinicaltrials.gov/show/NCT04261270']A Randomized, Open, Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia[/URL] [/TD][TD] 60 [/TD][TD] China [/TD][TD] May 1, 2020 [/TD][/TR] [TR][TD] Tocilizumab [/TD][TD] [URL='https://clinicaltrials.gov/show/NCT04320615']COVACTA: A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia[/URL] [/TD][TD] 330 [/TD][TD] US [/TD][TD] August 31, 2021 [/TD][/TR] [TR][TD] Tocilizumab, sarilumab [/TD][TD] [URL='https://clinicaltrials.gov/show/NCT04322773']TOCIVID: Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure[/URL] [/TD][TD] 200 [/TD][TD] Denmark [/TD][TD] June 1, 2021 [/TD][/TR] [TR][TH]Human Product RCTs[/TH][TD] [/TD][TD] [/TD][TD] [/TD][TD] [/TD][/TR] [TR][TD] Convalescent plasma [/TD][TD] [URL='https://clinicaltrials.gov/show/NCT04323800']CSSC-OO1: Efficacy and Safety Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune Plasma) Among Adults Exposed to COVID-19[/URL] [/TD][TD] 150 [/TD][TD] US [/TD][TD] December 31, 2022 [/TD][/TR] [TR][TD] Stem cells [/TD][TD] [URL='https://clinicaltrials.gov/show/NCT04273646']Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia[/URL] [/TD][TD] 48 [/TD][TD] China [/TD][TD] June 30, 2020 [/TD][/TR] [TR][TD] Stem cells [/TD][TD] [URL='https://clinicaltrials.gov/show/NCT04288102']Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19)[/URL] [/TD][TD] 90 [/TD][TD] China [/TD][TD] December 31, 2020 [/TD][/TR] [TR][TD] Natural-killer cells [/TD][TD] [URL='https://clinicaltrials.gov/show/NCT04280224']NK Cells Treatment for Novel Coronavirus Pneumonia[/URL] [/TD][TD] 30 [/TD][TD] China [/TD][TD] September 30, 2020 [/TD][/TR] [TR][TH]Vitamin C RCTs[/TH][TD] [/TD][TD] [/TD][TD] [/TD][TD] [/TD][/TR] [TR][TD] Vitamin C (high-dose IV) [/TD][TD] [URL='https://clinicaltrials.gov/show/NCT03680274']LOVIT: Lessening Organ Dysfunction With VITamin C[/URL] [/TD][TD] 800 [/TD][TD] Canada [/TD][TD] December 31, 2021 [/TD][/TR] [TR][TD] Vitamin C (high-dose IV) [/TD][TD] [URL='https://clinicaltrials.gov/show/NCT04264533']Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia[/URL] [/TD][TD] 140 [/TD][TD] China [/TD][TD] September 30, 2020 [/TD][/TR] [TR][TH](Hydroxy)Chloroquine RCTs[/TH][TD] [/TD][TD] [/TD][TD] [/TD][TD] [/TD][/TR] [TR][TD] Chloroquine, azithromycin [/TD][TD] [URL='https://clinicaltrials.gov/show/NCT04324463']ACT COVID19: Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial[/URL] [/TD][TD] 1500 [/TD][TD] Canada "+ international" [/TD][TD] September 30, 2020 [/TD][/TR] [TR][TD] Hydroxychloroquine [/TD][TD] [URL='https://clinicaltrials.gov/ct2/show/NCT04308668?term=NCT04308668&draw=2&rank=1']COVID-19 PEP: Post-Exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2[/URL] [/TD][TD] 3000 [/TD][TD] Canada, US [/TD][TD] April 21, 2020 [/TD][/TR] [TR][TD] Hydroxychloroquine [/TD][TD] [URL='https://clinicaltrials.gov/show/NCT04261517']Efficacy and Safety of Hydroxychloroquine for Treatment of Pneumonia Caused by 2019-nCoV (HC-nCoV )[/URL] [/TD][TD] 30 [/TD][TD] China [/TD][TD] February 25, 2020 [/TD][/TR] [TR][TD] Hydroxychloroquine [/TD][TD] [URL='https://www.medrxiv.org/content/10.1101/2020.03.22.20040758v2']Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial[/URL] [/TD][TD] 62 [/TD][TD] China [/TD][TD] February 28, 2020 [/TD][/TR] [TR][TD] Hydroxychloroquine [/TD][TD] [URL='https://clinicaltrials.gov/show/NCT04318444']Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19) [includes treatment of early symptoms][/URL] [/TD][TD] 1600 [/TD][TD] US [/TD][TD] March 1, 2021 [/TD][/TR] [TR][TD] Hydroxychloroquine, azithromycin [/TD][TD] [URL='https://clinicaltrials.gov/show/NCT04321278']Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)[/URL] [/TD][TD] 440 [/TD][TD] Brazil [/TD][TD] August 30, 2020 [/TD][/TR] [TR][TH]Other RCTs[/TH][TD] [/TD][TD] [/TD][TD] [/TD][TD] [/TD][/TR] [TR][TD] Chinese medicine [/TD][TD] [URL='https://clinicaltrials.gov/show/NCT04278963']Yinhu Qingwen Decoction for the Treatment of Mild/Common CoVID-19[/URL] [/TD][TD] 300 [/TD][TD] China [/TD][TD] January 1, 2021 [/TD][/TR] [TR][TD] Chinese medicine [/TD][TD] [URL='https://clinicaltrials.gov/show/NCT04310865']Yinhu Qingwen Granula for the Treatment of Severe CoVID-19[/URL] [/TD][TD] 116 [/TD][TD] China [/TD][TD] March 30, 2021 [/TD][/TR] [TR][TD] Chinese medicine, N-acetylcysteine (cysteine supplement) [/TD][TD] [URL='https://clinicaltrials.gov/show/NCT04279197']Treatment of Pulmonary Fibrosis Due to 2019-nCoV Pneumonia With Fuzheng Huayu[/URL] [/TD][TD] 136 [/TD][TD] China [/TD][TD] December 1, 2022 [/TD][/TR] [TR][TD] Colchicine [/TD][TD] [URL='https://clinicaltrials.gov/show/NCT04322682']COLCORONA: Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)[/URL] [/TD][TD] 6000 [/TD][TD] Canada [/TD][TD] September 1, 2020 [/TD][/TR] [TR][TD] Immunoglobulin [/TD][TD] [URL='https://clinicaltrials.gov/show/NCT04261426']The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia[/URL] [/TD][TD] 80 [/TD][TD] China [/TD][TD] April 30, 2020 [/TD][/TR] [TR][TD] Interferon, arbidol hydrochloride [/TD][TD] [URL='https://clinicaltrials.gov/show/NCT04254874']A Prospective/Retrospective, Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia[/URL] [/TD][TD] 100 [/TD][TD] China [/TD][TD] June 1, 2020 [/TD][/TR] [TR][TD] Losartan [/TD][TD] [URL='https://clinicaltrials.gov/show/NCT04311177']Losartan for Patients With COVID-19 Not Requiring Hospitalization[/URL] [/TD][TD] 516 [/TD][TD] US [/TD][TD] April 1, 2021 [/TD][/TR] [TR][TD] Losartan [/TD][TD] [URL='https://clinicaltrials.gov/show/NCT04312009']Losartan for Patients With COVID-19 Requiring Hospitalization[/URL] [/TD][TD] 200 [/TD][TD] US [/TD][TD] April 1, 2021 [/TD][/TR] [TR][TD] Methylprednisolone [/TD][TD] [URL='https://clinicaltrials.gov/show/NCT04244591']Steroids-SARI: Glucocorticoid Therapy for Novel Coronavirus Critically Ill Patients With Severe Acute Respiratory Failure[/URL] [/TD][TD] 80 [/TD][TD] China [/TD][TD] April 25, 2020 [/TD][/TR] [TR][TD] Methylprednisolone [/TD][TD] [URL='https://clinicaltrials.gov/show/NCT04263402']The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia[/URL] [/TD][TD] 100 [/TD][TD] China [/TD][TD] June 1, 2020 [/TD][/TR] [TR][TD] Methylprednisolone [/TD][TD] [URL='https://clinicaltrials.gov/show/NCT04273321']Efficacy and Safety of Corticosteroids in COVID-19[/URL] [/TD][TD] 400 [/TD][TD] China [/TD][TD] May 1, 2020 [/TD][/TR] [TR][TD] Nitric oxide gas [/TD][TD] [URL='https://clinicaltrials.gov/show/NCT04305457']NoCovid: Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19[/URL] [/TD][TD] 240 [/TD][TD] US, China, Italy [/TD][TD] April 1, 2021 [/TD][/TR] [TR][TD] Nitric oxide gas [/TD][TD] [URL='https://clinicaltrials.gov/show/NCT04306393']NOSARSCOVID: Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19[/URL] [/TD][TD] 200 [/TD][TD] US, China, Italy [/TD][TD] March 21, 2021 [/TD][/TR] [TR][TD] PUL-042 inhalation solution [/TD][TD] [URL='https://clinicaltrials.gov/show/NCT04312997']PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection[/URL] [/TD][TD] 100 [/TD][TD] US [/TD][TD] September 1, 2020 [/TD][/TR] [TR][TD] Tetrandrine [/TD][TD] [URL='https://clinicaltrials.gov/show/NCT04308317']TT-NPC: Tetrandrine Tablets Used in the Treatment of COVID-19[/URL] [/TD][TD] 60 [/TD][TD] China [/TD][TD] March 1, 2021 [/TD][/TR][/TABLE] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
General Health & Fitness
Health & Wellness
Coronavirus COVID-19 Update: Hydroxychloroquine and Other Treatments
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top